Full Year 2025 Telix Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Telix Pharmaceuticals Ltd (TLPPF) reported a 56% growth in revenue to $804 million, marking the third consecutive year of double-digit revenue growth.
- The precision medicine business saw a 22% year-over-year increase in revenue, with EBITDA improving by 25% to $216 million.
- The company successfully launched Gozelix, which has been FDA approved and is expected to drive future revenue growth.
- Telix Pharmaceuticals Ltd (TLPPF) has a robust pipeline with over 30 sponsored and collaborative studies, including pivotal trials that are expected to generate significant commercial and financial inflection points.
- The company maintains a solid cash balance of $142 million, allowing it to self-fund R&D investments and commercial infrastructure without shareholder dilution.
- The European market for Telix Pharmaceuticals Ltd (TLPPF)'s products is experiencing delays due to the complex reimbursement landscape, which can take 9 to 12 months post-approval.
- Gross margins for the RLS business segment are lower due to the commoditized nature of third-party nuclear medicine products.
- The company faces ongoing competitive pressure in the precision medicine market, which could impact future growth.
- There are uncertainties regarding the timeline for FDA review and approval of new products, which could affect the launch schedule.
- Telix Pharmaceuticals Ltd (TLPPF) plans to reinvest earnings into R&D and commercial expansion, potentially impacting short-term profitability.
Good day and thank you for standing by. Welcome to the Telix full year 2025 results and investor webcast. (Operator Instructions) Please be advised that today's conference is being recorded.
And now I'd like to hand the conference over to your speaker today, Kyahn Williamson, SVP of Investor Relations and Corporate Communications. Please go ahead.
Thank you and thank you to everybody for joining us on this call this morning. This evening where you are in the world, we lost our annual report full year results on the ASX, about 30 minutes ago. We also have the slides on screen via webcast for UC today. I'm just going to take you through a brief introduction, and some disclaimer statements before handing over, but I, if you just move to the slide 2, you're pleased to have on the call with us today. Chris Behrenbruch, our CEO and Managing Director; Darren Smith, our CFO; and Kevin Richardson, our CEO of the Precision Medicine business. I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
